Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.

While SARS-CoV-2 has some similarities to the SARS-CoV pathogen that led to an epidemic in 2002 and 2003, there is much about the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of the novel virus that remains unknown.3 Additional research is needed to explore the nature of the virus, its spectrum of disease, and potential therapies to combat its spread. The aim of this project will be to establish a biorepository of blood samples from patients infected with SARS-CoV-2 that can then be used by investigators to expand our understanding of COVID-19 and its treatment and, in turn, improve patient outcomes.

The COVID-19 biorepository will accomplish the following specific aims:

1. Establish a collection of biospecimens from patients with COVID-19.
2. Establish a link between biospecimens and longitudinal individual patient data, which will be collected and stored in RedCap.
3. Provide biospecimens and unique patient data to researchers investigating COVID-19. Separate IRB approval will be needed for these studies.

Inclusion Criteria:

• The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP).
• The participant has a diagnosis of COVID-19 confirmed by COVID-19 PCR.
• Patient is 18 years of age or older.

Exclusion Criteria:

• Participant declines to participate (living patients only)
• Participant or healthcare surrogate is unable to provide informed consent (living patients only)

COVID-19-positive patients